CRSP vs MSCI: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CRSP and MSCI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CRSP and MSCI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

CRISPR Therapeutics AG is a Swiss-American biopharmaceutical company headquartered in Zug, Switzerland, with principal research operations in Boston, Massachusetts. The company uses its proprietary CRISPR/Cas9 platform to develop gene-based medicines across hemoglobinopathies, oncology, cardiovascular disease, autoimmune conditions, and regenerative medicine. Its first and only commercialized product, Casgevy, is co-developed and co-commercialized with Vertex Pharmaceuticals under a 40/60 profit-sharing structure in which CRISPR retains 40 percent of profits. Revenue has historically been driven by collaboration milestone payments from Vertex rather than product sales, making the financial profile highly lumpy. Beyond Casgevy, the company generates no meaningful product revenue today and funds operations through its cash reserves.

Full CRSP guide

MSCI Inc. builds and licenses investment tools that asset managers, banks, and asset owners use to construct and measure portfolios. Its four reporting lines are Index (the MSCI World, Emerging Markets, ACWI, and factor indexes that thousands of ETFs and funds track), Analytics (risk and performance models like Barra and RiskMetrics), Sustainability and Climate (formerly ESG and Climate ratings and data), and Private Assets (real-estate and private-capital tools from the Burgiss and RCA acquisitions). The Index unit is the profit engine: it earns recurring subscription fees plus asset-based fees that scale with the assets under management in products linked to MSCI indexes.

Full MSCI guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CRSP drivers: First-Mover Advantage in Commercial Gene Editing; Casgevy's Long-Term Revenue Potential.
• MSCI drivers: Passive investing and asset-based fees; Recurring subscriptions and pricing power.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The commercial ramp of Casgevy has been far slower than early projections, with the therapy generating only approximately $3.5 million in revenue in all of 2025, down sharply from prior years that were boosted by one-time milestone payments. For MSCI, mSCI carries a premium valuation, so any deceleration in subscription growth or index-linked flows can compress the multiple sharply.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CRSP if you believe its drivers more; MSCI if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CRSP and MSCI guides.

CRSP. Because CRISPR Therapeutics has no meaningful product profits yet, traditional earnings-based valuation multiples like P/E are negative and not analytically useful. The company is better evaluated on its cash runway, the pace of Casgevy's commercial adoption, and the risk-adjusted value of its pipeline. Enterprise value of roughly $2.8 billion (market cap less net cash) reflects the market pricing in significant execution uncertainty around both the Casgevy ramp and the broader pipeline, while a wide spread exists between bearish analyst targets near $33 and optimistic targets above $80.

MSCI. MSCI trades at a premium earnings multiple (trailing P/E in the mid-30s, below its 10-year average near 42) that reflects its recurring revenue, wide moat, and high margins. Q1 2026 revenue grew about 14% to roughly $851 million with net income up sharply and the index asset-based fee run rate at a record. Shares were around $600 with roughly 73 million shares outstanding.

Headline figures (approximate, June 27, 2026 (data reflects most recently available reports through mid-2026)): CRSP shows revenue (full year 2025, product only) ~$3.5 million, revenue (full year 2024) ~$37.3 million (primarily collaboration revenue), net loss (ttm through q3 2025) ~$488 million, operating loss (full year 2025) ~$665 million; MSCI shows revenue (ttm) ~$3.2B, q1 2026 revenue ~$851M (up ~14% YoY), operating margin ~54%, market cap ~$44B.

CRSP and MSCI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CRSP and MSCI exposure against your real portfolio. It is not an investment adviser.